NCT01380509

Bioavailability Study of Metronidazole Capsules Under Fasting Conditions

To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules( G.D. Searle, Inc) Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Par Pharmaceutical, Inc. · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the single-dose Bioavailability of Kali and G.D. Searle, Inc.

Detailed description

To compare the relative Bioavailability of Metronidazole 375 mg Capsules with that of Flagyl 375 mg Capsules in healthy, adult subjects under fasting conditions

Conditions

• To Determine the Bioequivalence Study Under Fasting

Interventions

Type	Name	Description
DRUG	Metronidazole	Capsules, single-dose, fasting
DRUG	Flagyl	Capsules, single-dose, fasting

Timeline

• Start date: 2002-08-01
• Primary completion: 2002-09-01
• Completion: 2002-10-01
• First posted: 2011-06-27
• Last updated: 2011-06-27

Locations

1 site across 1 country: Canada